Maintenance Pembrolizumab-Olaparib Fails to Boost Survival in TNBC

(MedPage Today) -- SAN ANTONIO -- A maintenance strategy involving checkpoint blockade and a PARP inhibitor after first-line therapy did not improve survival outcomes in unselected patients with triple-negative breast cancer (TNBC), though was...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news